1921 related articles for article (PubMed ID: 8621260)
1. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results.
Lasek W; Giermasz A; Kuc K; Wańkowicz A; Feleszko W; Gołab J; Zagozdzon R; Stokłosa T; Jakóbisiak M
Int J Cancer; 1996 May; 66(3):374-9. PubMed ID: 8621260
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice.
Lasek W; Wańkowicz A; Kuc K; Feleszko W; Giermasz A; Jakóbisiak M
Oncology; 1996; 53(1):31-7. PubMed ID: 8570128
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
Feleszko W; Lasek W; Gołab J; Jakóbisiak M
Neoplasma; 1995; 42(2):69-74. PubMed ID: 7617079
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin.
Sora MK; Kruszewski AA; Stokłosa T; Czyzyk J; Lasek W; Malejczyk J; Jakóbisiak M
Arch Immunol Ther Exp (Warsz); 1994; 42(4):269-74. PubMed ID: 7487365
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
Marks TA; Venditti JM
Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
7. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
Lasek W; Sora M; Wańkowicz A; Jakóbisiak M
Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296
[TBL] [Abstract][Full Text] [Related]
8. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice.
Lasek W; Feleszko W; Golab J; Stokłosa T; Marczak M; Dabrowska A; Malejczyk M; Jakóbisiak M
Cancer Immunol Immunother; 1997 Oct; 45(2):100-8. PubMed ID: 9390201
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
11. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.
Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM
Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo anti-tumor activity of L-glutamic acid gamma-monohydroxamate against L1210 leukemia and B16 melanoma.
Vila J; Thomasset N; Navarro C; Doré JF
Int J Cancer; 1990 Apr; 45(4):737-43. PubMed ID: 2323850
[TBL] [Abstract][Full Text] [Related]
13. Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice.
Giermasz A; Makowski M; Nowis D; Jalili A; Maj M; Dabrowska A; Czajka A; Jakobisiak M; Golab J
Oncol Rep; 2002; 9(1):199-203. PubMed ID: 11748483
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
15. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution.
Chokri M; Freudenberg M; Galanos C; Poindron P; Bartholeyns J
Anticancer Res; 1989; 9(4):1185-90. PubMed ID: 2817800
[TBL] [Abstract][Full Text] [Related]
17. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
Stoychkov JN; Miloushev AS
Biomedicine; 1980 Apr; 33(2):42-4. PubMed ID: 6447522
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice.
Lasek W; Wańkowicz A; Kuc K; Feleszko W; Gołab J; Giermasz A; Wiktor-Jedrzejczak W; Jakóbisiak M
Cancer Immunol Immunother; 1995 May; 40(5):315-21. PubMed ID: 7600564
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
